Navigation Links
Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
Date:9/18/2008

BOSTON, Sept. 18 /PRNewswire/ -- Scimitar Equity, LLC issues a Q4/08 review of Neurobiological Technologies, Inc. (Nasdaq: NTII), entitled, "Defining Outcome Scenarios, Probabilities Appear Focused to the Upside and Future Appreciation." This review is available at our website: http://www.scimitarequity.com

Neurobiological Technologies, Inc. (NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. NTII is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. Neurobiological Technologies, Inc. is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. For further information, please visit NTII's website at http://www.ntii.com

Scimitar Equity, LLC provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about NTII (NASDAQ) and its or their securities. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.

CONTACT:

Scimitar Equity, LLC

Henry W. McCusker

Director of Research

phone: (617) 559.1080

e-mail: hwm@scimitarequity.com


'/>"/>
SOURCE Scimitar Equity, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
2. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
3. Neurobiological Technologies CEO to Retire on December 31, 2008
4. Neurobiological Technologies Reports Third Quarter Financial Results
5. Neurobiological Technologies Sets Date for Third Quarter Financial Results
6. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
7. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
8. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
9. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
10. Neurobiological Technologies Sets Date for Research and Development Day
11. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016   BioInformant ... report, "Stem Cell Research Products, Opportunities, Tools, and Technologies ... ... in the stem cell industry, BioInformant has more than ... the stem cell market, by stem cell type. This ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global ... new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to distribute exosome injection ... American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... -- The Maryland House of Delegates and House Speaker ... Maryland School of Medicine Dean E. Albert Reece ... System President and CEO Robert Chrencik , MBA, ... given to the public by the leader of the ... and Mr. Chrencik for their contributions to our statewide ...
Breaking Biology Technology:
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint ... that Rising Market Are you interested in ... forecasts revenues for checkpoint inhibitors. Visiongain,s report gives ... submarket, product and national level. Avoid falling ... what progress, opportunities and revenues those emerging cancer ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
Breaking Biology News(10 mins):